Summary & Overview
HCPCS Q4081: Injection, Epoetin Alfa 100 Units (ESRD on Dialysis)
HCPCS Level II code Q4081 denotes an injection of epoetin alfa, 100 units, used to treat anemia in patients with end-stage renal disease (ESRD) receiving dialysis. This code captures administration of an erythropoiesis-stimulating agent in settings where dialysis care is delivered and is relevant to outpatient dialysis centers and related infusion sites. Nationally, accurate coding of Q4081 affects quality reporting, medication utilization tracking, and reimbursement flows for dialysis providers.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the code's clinical context, typical service setting, and common billing considerations. The publication also provides benchmarking context and policy-relevant notes to help stakeholders understand how Q4081 is positioned in payer coverage and billing workflows.
The analysis covers: what the code represents, the clinical rationale for epoetin alfa use in dialysis-dependent ESRD, expected sites of service, and areas where coding precision matters for reporting and payment. Data not available in the input is explicitly noted where applicable in supporting sections.
Billing Code Overview
HCPCS Level II code Q4081 describes an injection of epoetin alfa, 100 units, intended for patients with end-stage renal disease (ESRD) on dialysis. This service represents administration of an erythropoiesis-stimulating agent to manage anemia associated with dialysis-dependent kidney failure.
-
Service type: Parenteral medication administration (injectable biologic)
-
Typical site of service: Dialysis center or other outpatient infusion/administration setting where dialysis patients receive treatment
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with end-stage renal disease (ESRD) receiving maintenance hemodialysis in an outpatient dialysis center. The patient has symptomatic or laboratory-confirmed anemia related to chronic kidney disease and requires routine therapy with epoetin alfa to maintain hemoglobin within target range. During a dialysis session, the nephrology nurse or dialysis clinician administers Q4081 (injection, epoetin alfa, 100 units) via the patient’s vascular access or established intramuscular/subcutaneous site per facility protocol. The clinical workflow includes verification of physician orders, review of most recent hemoglobin and iron studies, documenting dose and lot number, monitoring for immediate adverse reactions, and recording administration in the dialysis treatment record and billing system. Typical documentation elements include indication (ESRD-related anemia), pre- and post-injection vitals if indicated, site of administration, amount (number of units and corresponding Q4081 units), lot number, and clinician credentials. Billing to payors such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare follows facility-based HCPCS reporting conventions for injectable biologics given during dialysis sessions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JZ | Drug wastage not billed to payer; full vial used |